Nasdaq
$7.99▼ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $585.1MShares out 73.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 10.2After-hours26.10.03 06:574Ownership#●●●
Candel Therapeutics, Inc.
Insider Nicoletta Loggia of Candel Therapeutics (CADL) reported a change in beneficial ownership of securities effective September 30, 2026. This filing serves as a standard disclosure of insider equity transactions via Form 4.…more
$7.99-0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 06:564Ownership
Candel Therapeutics, Inc.
Insider Joseph C. Papa of Candel Therapeutics, Inc. reported changes in beneficial ownership of securities effective September 30, 2026. This filing provides the details of the insider's equity transaction as required by Form 4.…more
$7.99-0.31%vs prev closeView filingShare - 10.2After-hours26.10.03 06:544Ownership
Candel Therapeutics, Inc.
Insider Paul B. Manning of Candel Therapeutics, Inc. filed a Form 4 report regarding his beneficial ownership of securities as of September 30, 2026. This filing serves as an official disclosure of changes in insider holdings.…more
$7.99-0.31%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:05#●●●#●●●
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
Candel Therapeutics has appointed legal expert Maria Ostrovsky as its new General Counsel. This appointment is intended to strengthen the company's legal and compliance capabilities as it prepares for a planned BLA submission and potential commercialization.…more
$7.99-0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2Pre-market26.10.02 22:00
●●●●●●●● ●●●●● ●●●●●●
Candel Therapeutics will present clinical data for its NSCLC and glioblastoma immunotherapy candidates at the SITC 2026 Annual Meeting. As these are scientific poster presentations, the immediate financial impact on the stock remains neutral.…more
$7.99-0.31%vs prev close - 10.1After-hours26.10.02 05:05
●●●●●●●● ●●●●● ●●●●●●
Candel Therapeutics has granted stock options for a total of 85,900 shares to four new employees under Nasdaq listing rules. This is a standard recruitment incentive and does not reflect changes in the company's financial performance.…more
$7.99-0.31%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report